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Identity 
Other names: IPFK2, PFK2 
HGNC (Hugo): PFKFB3 
Location: 10p15.1 
Note: The human PFKFB3 gene is located on the 
short arm of chromosome 10 at position 10p15.1  
(Manzano et al., 1998) (Figure 1). 
Location in the mouse: chromosome 2, 8,73 cM, 
11471430-11502101 bp, complement strand (MGI). 
For a comparison of the gene of Homo sapiens, mouse, 
rat, cattle, chimpanzee and domestic dog see: (MGI). 
Also for all species known gene tree, see: Treefam 
database. 
 
Figure 1. Localization of human PFKFB3 gene by in situ hybridization. 
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Figure 2. Splicing pattern of the human PFKFB3 gene. Schematic organization of the human PFKFB3 gene generated by alternative 
splicing and the protein sequence derived. The sequences of UBI2K4 and UBI2K5 isoforms corresponds to iPFKFB3 and uPFKFB3, 
respectively. 
 
DNA/RNA 
Description 
The human PFKFB3 is composed of 19 exons spanning 
genomic region about 90,6 Kb (GenBank).  
Alternative splicing variants have been reported. The 
main variants corresponding to mRNAs of 4453 bp and 
4224 bp for the variant 1 u-PFK2 (NM_004566.3) and 
variant 2 i-PFK2 (NM_001145443.1), respectively 
(Figure 2). 
Transcription 
The human PFKFB3 coding sequence consists of 1503 
bp for i-PFK2 and 1563 bp for u-PFK2 from the start 
codon to the stop codon.  
Multiple alternatively spliced transcript variants have 
been found for this gene. (Entrez Gene) 
(OTTMUSG00000011314). 
Pseudogene 
No pseudogene of PFKFB3 known. 
 
 
Protein 
Description 
PFKFB3 protein consists of two homodimeric subunits 
of 520 amino acids, with a molecular weight of 59609 
Da for each subunit.  
The monomer structure is divided into two functional 
domains within the same polypeptidic chain (El-
Maghrabi et al., 1982; Okar et al., 2001; Pilkis et al., 
1995).  
The finding of mutations that affect kinase activity of 
the enzyme (Kurland et al., 1995; Li et al., 1992b; 
Rider et al., 1994), and the localization of ATPγS in the 
structure, lead to the identification of the N-terminal 
domain as the kinase domain, which catalyses the 
synthesis of Fru-2,6-P2, using fructose-6-phosphate and 
adenosine-5-triphosphate (ATP) as substrates (Figure 
3). 
On the other hand, structural and sequence homology 
with yeast phosphoglycerate mutase (Winn et al., 1981) 
and rat acid phosphatase (Schneider et al., 1993), along 
with the location of  
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mutations that affect Fru-2,6-Pase activity (Li et al., 
1992a; Li et al., 1992c; Lin et al., 1992; Tauler et al., 
1990) suggested the C-terminal domain to contain the 
bisphosphatase activity of the enzyme. 
This domain is responsible for the hydrolytic 
degradation of Fru-2,6-P2 into fructose-6-P and 
inorganic phosphate (Pi).  
These two mutually opposing catalytic activities are 
controlled by different mechanisms such that either 
activity is predominant in a given physiological 
condition. Ultimately, 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase (PFK-2/FBPase-2) 
activities control Fru-2,6-P2 synthesis and degradation, 
regulating the rate of glucose metabolism. 
Different PFK-2/FBPase-2 isoenzymes have been 
described, sharing high sequence similarity (85%). 
PFKFB3 isoenzyme has some structural differences 
with the other isoforms.  
The conformations of the substrate loops in the kinase 
domain are different from those of other isoforms 
(Hasemann et al., 1996; Lee et al., 2003), giving a 
structural explanation for the higher kinase activity. 
Moreover, the N-terminus binds to the bisphosphatase 
domain to produce a conformational change in the 
active pocket to enhance inhibitory binding of product 
(Kim et al., 2006). Residues 4-15 of the kinase domain 
form a β-hairpin structure and the rest is used as an arm 
connecting the hairpin  
to the bisphosphatase domain. Additionally, the 
contacting area of the bisphosphatase domain is 
functionally very sensitive due to the residues critical 
for binding of both product and substrate are located 
very close (Kim et al., 2006). The low bisphosphatase 
activity of PFKFB3, which is lower than that of other 
isoforms by an order of magnitude, is due to the 
presence of a serine at residue 302 instead of an 
arginine as conserved in the other isoforms. This 
residue is said to interact with the 2-phosphate and 
further stabilizes the transitions state (Cavalier et al., 
2012; Kim et al., 2006). 
Expression 
The PFKFB3 gene product is present in proliferating 
tissues (Duran et al., 2008a; Duran et al., 2009; Goren 
et al., 2000; Manzano et al., 1998; Sakai et al., 1996) 
and transformed cells (Calvo et al., 2006; Chesney et 
al., 1999; Hamilton et al., 1997; Minchenko et al., 
2002; Novellasdemunt et al., 2012; Obach et al., 2004; 
Riera et al., 2002) and various tumors (Atsumi et al., 
2002; Fleischer et al., 2011; Kessler et al., 2008). The 
high kinase/ bisphosphatase activity ratio of this 
isoenzyme can explain the high Fru-2,6-P2 found in the 
cells where it is present, which in turn sustains high 
glycolytic rates and it is crucial in supporting growing 
and proliferant cell metabolism. 
 
Figure 3. Scheme of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-2/FBPase-2) activity. PFKFB3 protein 
consists of two homodimeric subunits of 59,6 KDa. The monomer structure contains two functional domains; kinase and bisphosphatase, 
located at N-terminal and C-terminal regions, respectively. PFKFB3 has the highest Kinase/Bisphosphatase activity ratio (K/B=700) 
which promotes high concentrations of Fru-2,6-P2. 
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PFKFB3 gene has been found to be expressed in 
different cell systems. During C2C12 myogenic cell 
differentiation, the 6-phosphofructo-2-kinase 
isoenzyme, product of the PFKFB3 gene, is 
downregulated, being the PFKFB3 isoenzyme degraded 
through the ubiquitin-proteasome proteolytic pathway 
(Riera et al., 2003). In neurons, PFKFB3 is constantly 
subjected to proteasome degradation after 
ubiquitylation by the E3 ubiquitin ligase APC/C-Cdh1. 
The activity of this complex is determinant in 
controlling the protein levels of PFKFB3 and hence the 
rate of glucose consumption through glycolysis. The 
function of APC/C is strictly dependent on the presence 
of Cdh1, which is very abundant in these cells. In 
contrast, astrocytes express very low Cdh1 levels and 
therefore APC/C activity is negligible. Accordingly, 
PFKFB3 protein levels are high and glycolysis is active 
in astrocytes owing to the low levels of Cdh1. In fact, 
overexpression of Cdh1 in astrocytes destabilizes 
PFKFB3 and concomitantly decreases the rate of 
glycolysis (Fernandez-Fernandez et al., 2012). The 
later finding that the activity of the PFKFB3 isoenzyme 
is regulated in cancer cells by APC/C-Cdh1 (Almeida 
et al., 2010) led to the identification of the role of this 
ubiquitin ligase in the metabolic regulation of the cell 
cycle and therefore of cell proliferation (Moncada et 
al., 2012). 
The regulatory component of this complex, Cdh1, has 
been shown to be downregulated during malignant 
progression and tumor formation. A decrease in the 
activity of APC/C-Cdh1 in mid-to-late G1 phase, that 
has been described as the nutrient-sensitive restriction 
point and is responsible for the transition from G1 to S, 
leads to the accumulation of PFKFB3 and enhances the 
glycolytic flux in malignant cells. PFKFB3 is also a 
substrate at the onset of S-phase for the ubiquitin ligase 
SCF (Skp1/cullin/F-box)-β-TrCP (β-transducin repeat-
containing protein), so that the activity of PFKFB3 is 
short-lasting, coinciding with a peak in glycolysis in 
mid-to-late G1, demonstrating that proliferation and the 
induction of aerobic glycolysis are both essential 
components of neoplastic transformation (Moncada et 
al., 2012). 
PFKFB3 has also been found in testis. In adult testes 
both PFKFB3 and PFKFB4 isoenzymes are present. 
PFKFB3 is located across the seminiferous epithelium, 
whereas expression of PFKFB4 is restricted to the 
spermatogenic cells, being the only one present in 
mature spermatozoa (Gomez et al.,  
2005). This differential distribution supports the idea 
that the cell-specific isoenzymes are able to adapt their 
kinetic and regulatory enzymatic properties to the 
metabolic demand of a particular tissue or cell status. 
Thus, in parallel with spermatogenesis and 
spermiogenesis, PFKFB isoenzyme expression 
switches from PFKFB3, which is required during the 
proliferative phase, to the testis isoform PFKFB4, 
which is germ cell specific (Gomez et al., 2012; Gomez 
et al., 2009). 
In mouse hypothalami, PFKFB3 mRNA levels are 
increased by 10-fold in response to re-feeding. In the 
hypothalamus, re-feeding also decreases the 
phosphorylation of AMP-activated protein kinase 
(AMPK) (Thr172) and the mRNA levels of agouti-
related protein (AgRP), and increases the mRNA levels 
of cocaine-amphetamine-related transcript (CART).  
In addition, knockdown of PFKFB3 in N-43/5 neurons 
causes a decrease in rates of glycolysis, which is 
accompanied by increased AMPK phosphorylation, 
increased AgRP mRNA levels and decreased CART 
mRNA levels. In contrast, overexpression of PFKFB3 
in N-43/5 neurons causes an increase in glycolysis, 
which was accompanied by decreased AMPK 
phosphorylation and decreased AgRP mRNA levels 
and increased CART mRNA levels. Together, these 
results suggest that PFKFB3 responds to re-feeding, 
which in turn stimulates hypothalamic glycolysis and 
decreases hypothalamic AMPK phosphorylation and 
alters neuropeptide expression in a pattern that is 
associated with suppression of food intake (Li et al., 
2012). 
Recent results have shown that the tumour suppressor 
PTEN promotes APC/C-Cdh1 activity (Song et al., 
2011) and that cells from mice overexpressing PTEN 
exhibit reduced glucose and glutamine uptake and are 
resistant to oncogenic transformation (Garcia-Cao et 
al., 2012). Studies on the possible connection between 
APC/C-Cdh1 and the metabolic effects of other tumour 
suppressors such as p53 (Feng and Levine, 2010) or 
known proto-oncogenes such as c-Myc (Morrish et al., 
2008) and Akt (Matheny and Adamo, 2009) are also 
likely to be highly relevant. 
Localisation 
PFKFB3 protein is predominantly cytoplasmic but it 
has been found also into the nucleus. PFKFB3 
overexpression produces a marked increase in cell 
proliferation.  
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Figure 4. PFKFB3 activities and function in the glycolytic pathway. 
Figure 5. Analysis of the 5' PFKFB3 human gene promoter region. Putative regulatory elements in the PFKFB3 gene promoter. 
Table I. Properties of PFKFB genes. 
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Function 
These effects on proliferation were completely 
abrogated by mutating either the active site or nuclear 
localization residues of PFKFB3, demonstrating a 
requirement for nuclear delivery of Fru-2,6-P2 which 
produced an increase in the expression of several key 
cell cycle proteins, including cyclin-dependent kinase 
Cdk1, Cdc25C, and cyclin D3 and decreased the 
expression of the cell cycle inhibitor p27, a universal 
inhibitor of Cdk-1 and the cell cycle, indicating that 
Fru-2,6-P2 may couple the activation of glucose 
metabolism with cell proliferation (Yalcin et al., 
2009a). 
Synthesis and degradation of fructose-2,6-
bisphosphate: 
- Kinase catalytic activity: ATP + D-fructose-6-
phosphate = ADP + beta-D-fructose-2,6-bisphosphate 
- Phosphatase catalytic activity: Beta-D-fructose-2,6-
bisphosphate + H2O = D-fructose-6-phosphate + 
phosphate 
The rate of glycolytic flux is controlled at different 
levels and by different mechanisms: substrate 
availability, enzyme concentrations, allosteric effectors 
and covalent modification on regulatory enzymes. One 
of the critically modulated steps is that catalysed by 6-
phosphofructo-1-kinase (PFK-1), with fructose-2,6-
bisphosphate (Fru-2,6-P2) being its most powerful 
allosteric activator (Okar and Lange, 1999; Rider et al., 
2004; Van Schaftingen, 1987).  
Fru-2,6-P2 relieves ATP inhibition and acts 
synergistically with AMP, and in addition it inhibits 
fructose 1,6-bisphosphatase (Van Schaftingen, 1987). 
These properties confer to this metabolite a key role in 
the control of fructose-6-P/fructose-1,6-P2 substrate 
cycle and hence critically regulate carbohydrate 
metabolism (Figure 4). 
PFKFB genes 
In mammals, there are four PFKFB genes (PFKFB1, 
PFKFB2, PFKFB3 and PFKFB4) which code for the 
different PFK-2/FBPase-2 isoenzymes, characterized 
by their cellular expression patterns. These isoforms 
share highly conserved core catalytic domains (85%) 
but differ greatly in their kinetic properties and 
responses to regulatory signals (Okar et al., 2001). 
These differences are mostly due to highly divergent N- 
and C-terminal regulatory domains; however, a few but 
significant sequence differences in the catalytic 
domains that constitute the secondary residue shells 
surrounding the active sites also contribute to the 
kinetic differences (Cavalier et al., 2012). 
These isoforms show differences in their distribution 
and kinetic properties in response to allosteric effectors, 
hormonal, and growth factor signals (Okar et al., 2001). 
The expression of these genes is dependent on tissue 
and on development stage (Goren et al., 2000). 
Importantly, tissue- and cell-specific isoenzymes are 
not totally exclusive and several cells express more 
than one isoenzyme (Calvo et al., 2006; Minchenko et 
al., 2005a; Minchenko et al., 2005b; Telang et al., 
2006).  
This pattern of expression suggests that each 
isoenzyme plays a key role under different 
physiological conditions or in response to different 
stimuli.  
Although the PFKFB isoenzymes have the same 
enzymatic activities and share the same substrates, 
indicating functional redundancy, their biological 
function and regulation is different in the specific cells 
(Table I). 
PFKFB1 is mainly expressed in liver and skeletal 
muscle, PFKFB2 in heart tissue, PFKFB3 is expressed 
ubiquitously in several tissue and proliferating cells, 
and PFKFB4 was originally found in testis (Okar et al., 
2001). 
PFKFB3 has a uniquely large 6-phosphofructo-2-
kinase to fructose-2,6-bisphosphatase activity ratio 
compared to other isoforms (Sakakibara et al., 1997).  
This isoform, which has a native activity ratio of 
roughly 700-fold kinase-to-phosphatase activity, 
dramatically increases upon phosphorylation of Ser461 
by protein kinase A (PKA), AMP-dependent protein 
kinase (AMPK) or other kinases.  
The low bisphosphatase activity of PFKFB3, which is 
lower than that of other isoforms by an order of 
magnitude, is solely due to the presence of a serine at 
residue 302 instead of an arginine as conserved in the 
other isoforms (Cavalier et al., 2012; Kim et al., 2006). 
PFKFB3 gene was cloned from a fetal brain library 
(Manzano et al., 1998; Ventura et al., 1995), human 
placenta (Sakai et al., 1996) and breast cancer cells 
(Hamilton et al., 1997). 
PFKFB3 is expressed ubiquitously and it is present in 
proliferating tissues, transformed cells and in tumours 
(Almeida et al., 2010; Atsumi et al., 2002; Bando et al., 
2005; Calvo et al., 2006; Chesney et al., 1999; Duran et 
al., 2008a; Duran et al., 2009; Kessler et al., 2008; 
Novellasdemunt et al., 2012; Riera et al., 2002; Yalcin 
et al., 2009b). An inducible PFK-2/FBPase-2 (iPFK-2) 
with proto-oncogenic features was cloned from cancer 
cell lines (Chesney et al., 1999).  
The iPFK-2 represents a splice product of the PFKFB3 
gene, as does the ubiquitous PFK-2/FBPase-2 (uPFK-
2) (Navarro-Sabate et al., 2001). In human brain, have 
been demonstrated the occurrence of six alternatively 
spliced PFKFB3 transcripts, designated UBI2K1-6 
splice isoforms of ubiquitous 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase (Kessler and 
Eschrich, 2001). 
Regulation: 
PFKFB3 gene is regulated by different mechanisms. 
Induction of its expression has been reported in 
response to different stimuli, amongst these are hypoxia 
(Bartrons and Caro, 2007; Minchenko et al., 2002; 
Obach et al., 2004) and progestins (Hamilton et al., 
1997; Novellasdemunt et al., 2012), through HIF 
(Hypoxia Inducible Factor) and PR (progesterone  
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receptor) interactions within their binding to the 
consensus HRE (Hypoxia response element) and PRE 
(progesterone response element) sites located at 
PFKFB3 promoter, respectively. Growth factors such 
as insulin (Riera et al., 2002) and pro-inflammatory 
molecules (Chesney et al., 1999) such as IL-6 (Ando et 
al., 2010), LPS and adenosine (Ruiz-Garcia et al., 
2011) or in response to stress stimuli (NaCl, H2O2, UV 
radiation or anisomycin) through SRF (Serum 
Response Factor) and its binding to SRE (Serum 
response element) site (Novellasdemunt et al., 2013) 
(Figure 5). The proinflammatory cytokine interleukin 
(Il-6) enhances glycolysis through activation of 
PFKFB3 as a consequence of the STAT3 activation 
(Ando et al., 2010). PFKFB3 is also a target gene of 
PPARγ. Additionally, PFKFB3 is involved in the 
antidiabetic effect of PPARγ activation, at least, by 
suppressing excessive fatty acid oxidation-related 
reactive oxygen species (ROS) production and 
inflammatory responses in adipose tissue/adipocytes 
(Huo et al., 2010). 
The product of the PFKFB3 gene, the bifunctional 
enzyme 6-phosphofructo-2-kinase/ fructose-2,6-
bisphosphatase, is also controlled by different 
mechanisms. In addition to the gene expression 
regulation, the C-terminal domain can be 
phosphorylated at Ser461 by different protein kinases, 
such as AMP-activated protein kinase (AMPK) (Bando 
et al., 2005; Marsin et al., 2002), RSK 
(Novellasdemunt et al., 2012) and MK2 
(Novellasdemunt et al., 2013) (Figure 6). 
Ser461 can also be phosphorylated by PKC and PKA 
making it responsive to multiple external signals 
(Okamura and Sakakibara, 1998). Phosphorylated 
PFKFB3 kinetics shows an increase in Vmax of the 
kinase activity and a decreased Km for Fru-6-P (Marsin 
et al., 2002; Novellasdemunt et al., 2012). Furthermore, 
the PFKFB3 isoenzyme was found to be regulated 
through the PI3K (phosphoinositide 3-
kinase)/Akt/mTOR (mammalian target of rapamycin) 
pathway, turning it into a target of growth factors 
signalling (Duran et al., 2009; Garcia-Cao et al., 2012) 
(Figure 7). 
Furthermore, the mRNAs of all PFKFB3 isoforms 
contain multiple copies of the AUUUA instability 
motif in its 30 untranslated region (30UTR) (Chesney 
et al., 1999). AU-rich elements (AREs) target them 
RNAs of proto-oncogenes and pro-inflammatory 
cytokines for rapid degradation and regulate the 
efficiency of their translation into proteins (Chen and 
Shyu, 1995). 
Also, PFKFB3 isoenzyme is regulated by modulation 
of its protein stability. Thus, it is degraded through the 
ubiquitin/proteasome proteolytic pathway (Riera et al., 
2003). PFKFB3 but not the other isoenzymes, contains 
a recognition signal composed of a K-E-N box 
(KENXXXN), where K is lysine, E is glutamate and N 
is asparagine, that is recognized by the anaphase-
promoting complex/cyclosome (APC/Cdh1), an E3 
ubiquitin ligase complex that plays an essential role in 
G1 phase and mitosis through the degradation of 
several cell cycle proteins and PFKFB3 (Almeida et al., 
2010). 
Homology 
It appears that the use of Fru-2,6-P2 as a regulatory 
metabolite is a specifically eukaryotic phenomenon. 
The most plausible hypothesis for the origin of the 
PFK-2/FBPase-2 would be the fusion of two ancestral 
genes coding for a kinase functional unit and a 
phosphohydrolase/mutase unit, respectively. From 
protein sequence alignments, it is clear that the 
bisphosphatase activity located in the C-terminal 
domain of the PFK-2/FBPase-2 is homologous to the 
phosphoglyceratemutases (PGMs) and the acid 
phosphatase family (Jedrzejas, 2000; Okar et al., 2001). 
Alignments of the bisphosphatase domain with PGM 
and acid phosphatase can be accessed at InterPro. 
The N-terminal PFK-2 domain is sequentially and 
structurally homologous to several nucleotide binding 
proteins, primarily that of adenylate kinase of E. coli. 
Mutations 
Note 
No PFKFB mutations have been collected in the 
COSMIC database. A lot of SNPs have been described, 
but they are not affecting to coding sequences. 2319 
NCBI SNPs in PFKFB3 are shown (GeneCard). 
Germinal 
No germinal mutations of PFKFB3 have been 
described. 
Somatic 
Loss of heterozygosity (LOH) of PFKFB3 has been 
found in 55% of glioblastomas. The allelic deletion of 
PFKFB3 resulted in a decrease of PFKFB3 mRNA 
level accompanied by a lower PFKFB3 protein level. 
The expression of growth-inhibiting splice variant 
UBI2K4 was effectively reduced in glioblastomas with 
PFKFB3 LOH and a positive correlation with overall 
PFKFB3 expression was observed. The PFKFB3 LOH 
as well as the resulting low UBI2K4 expression level 
was associated with a poor prognosis of glioblastoma 
patients. It was concluded that LOH on 10p14-p15 in 
glioblastomas targets PFKFB3 and in particular splice 
variant UBI2K4, a putative tumor suppressor protein in 
glioblastomas (Fleischer et al., 2011). 
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Figure 6. PFKFB3 phosphorylation sites. The residues Ser461 and Ser478 correspond to PFKFB3 isoenzyme and are equivalent to 
Ser466 and Ser483 of the PFKFB2 isoenzyme. The colours represent the phosphorylation residues (red), residues fully conserved in all 
or at least one of the isoforms (green), similar residues (yellow) and different residues (black). 
Figure 7. Differential physiological factors regulate PFKFB3 gene expression and its isoenzyme activity through phosphorylation of 
Ser461. 
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Implicated in 
Various cancers 
Prognosis 
At least 6 alternatively spliced variants of PFKFB3 
mRNA are known in humans (UBI2K1-6) (Figure 2). 
Thus, each might have a different contribution to 
prognosis of tumors. UBI2K5 and UBI2K6 are the 
predominant splice variants found in rapidly 
proliferating high-grade astrocytomas while the 
expression of UBI2K3 and UBI2K4 is mainly restricted 
to low-grade astrocytomas and non-neoplastic brain 
tissue (Zscharnack, 2009). 
Oncogenesis 
Enhanced glycolysis is important for oncogenesis and 
for the survival and proliferation of cancer cells in the 
tumor microenvironment. Neoplastic cells metabolize 
abundant glucose relative to normal cells in order to 
satisfy the increased energetic and anabolic needs of 
the transformed state. Moreover, most of tumours are 
subjected to hypoxic conditions due to the abnormal 
vasculature that supply them with oxygen and nutrients. 
A key step in controlling glycolytic rate is Fru-2,6-P2 
levels. This is controlled, in tumoral cells, mainly by 
PFKFB3 which, in turn, is activated by mitogenic, 
inflammatory and hypoxic stimuli, and is found to be 
constitutively expressed by several human leukemias 
and solid tumor cells (Bartrons and Caro, 2007; 
Chesney, 2006). 
Thyroid and ovarian cancer 
Note 
Increments in the expression of PFKFB3 mRNA and 
protein were reported in ovarian and thyroid 
carcinomas using in situ hybridization and 
immunohistochemistry analysis (Atsumi et al., 2002). 
Breast cancer 
Note 
PFKFB3 was firstly identified as a progesterone 
responding gene (PRG1) in human breast cancer cell 
lines (Hamilton et al., 1997). Afterwards, 
overexpression of PFKFB3 in T47D and MCF7 cells 
has been probed and the regulatory mechanism of the 
protein and gene regulation have been described 
(Novellasdemunt et al., 2012; Obach et al., 2004). 
PFKFB3 has also been identified, using loss-of-
function screen, as a gene required for cell growth and 
proliferation in CD44+CD24- human breast cancer 
cells (Marotta et al., 2011). 
Lung cancer 
Note 
Heterozygotic genomic deletion of the inducible 
PFKFB3 gene in ras-transformed mouse lung 
fibroblasts suppresses Fru-2,6-P2 production, glycolytic 
flux to lactate, and growth as soft agar colonies or 
tumors in athymic mice (Atsumi et al., 2002; Telang et 
al., 2006). 
Gastric and pancreas cancer 
Note 
The expression of PFKFB3 mRNA was observed in 
normal human gastric tissue and was increased in 
malignant gastric tumors. PFKFB3 gene is also 
expressed in gastric (MKN45, NUGC3) and pancreatic 
cancer cells (Panc1) which strongly respond to hypoxia 
via a HIF-1alpha dependent mechanism (Bobarykina et 
al., 2006). 
Colorectal cancer 
Note 
PFKFB3 gene expression is controlled by insulin in the 
human colon adenocarcinoma HT29 cell line (Riera et 
al., 2002). Overexpression of PFKFB3 isoenzyme and 
particularly the phosphorylated form (phospho-
PFKFB3 (Ser461)) has also been described in the 
human colon malignant tumors (Bando et al., 2005). 
Glioblastoma 
Note 
PFKFB3 protein levels were markedly elevated in 
high-grade astrocytomas relative to low-grade 
astrocytomas and corresponding non-neoplastic brain 
tissue, whereas no significant increase of PFKFB3 
mRNA was observed in high-grade astrocytomas when 
compared with control tissue. In the group of 
glioblastomas the PFKFB3 protein inversely correlates 
with EGFR expression. The findings demonstrate that 
PFKFB3 up-regulation is a hallmark of high-grade 
astrocytomas offering an explanation for high 
glycolytic flux and lactate production in these tumors 
(Kessler et al., 2008). 
The study of the different PFKFB isoenzymes showed 
that the splice variant UBI2K4 impeded the tumour cell 
growth and might serve as a tumour suppressor in 
astrocytic tumours (Zscharnack, 2009). In this sense, 
loss of heterozygocity on 10p14-p15 was detected in 
55% of glioblastomas and the allelic deletion of 
PFKFB3 splice variant UBI2K4 was associated with a 
poor prognosis (Fleischer et al., 2011). 
Neuronal diseases 
Note 
Strong evidence of linkage to late-onset Alzheimer 
disease (LOAD) has been observed on chromosome 10, 
which implicates a wide region and at least one 
disease-susceptibility locus. Although significant 
associations with several biological candidate genes, 
such as PFKFB3, on chromosome 10 have been 
reported, these findings have not been consistently 
replicated, and they remain controversial (Grupe et al., 
2006). 
Increased expression of HIF- 1α, as well as its target 
genes, VEGF, and PFKFB3 in both major depressive 
and bipolar disorder patients have been found in a 
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depressive state compared to healthy control subjects. 
The data suggest that altered expression of HIF-1 and 
its target genes mRNA in peripheral blood cells are 
associated - mainly in a state-dependent manner - with 
mood disorders. In addition, altered expression of HIF-
1 and its target genes may be associated with the 
pathophysiology of depression (Shibata et al., 2013). 
Diabetes and obesity 
Note 
Expression of PFKFB3 gene has been demonstrated in 
adipocytes (Atsumi et al., 2005). Single nucleotide 
polymorphism rs1064891, located in the 3' UTR of the 
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 
3 (PFKFB3) gene, was nominally associated with 
obesity in combined analysis of human cohorts (Jiao et 
al., 2008). In addition, it has been found that disruption 
of PFKFB3 gene ameliorates diet-induced adiposity but 
exacerbates systemic insulin resistance and adipose 
tissue inflammatory response (Huo et al., 2010).  
In contrast, overexpression of ubiquitous 6-
phosphofructo-2-kinase in the liver of transgenic mice 
results in weight gain (Duran et al., 2008b). 
Pfkfb3 gene expression is increased in streptozotocin-
induced diabetic mouse liver. During streptozotocin-
induced diabetes, phosphorylation of both p38 
mitogen-activated protein kinase and Akt was detected, 
together with the overexpression of the proliferative 
markers cyclin D and E2F.  
These findings indicate that PFKFB3 induction is 
coupled to enhanced hepatocyte proliferation in 
streptozotocin-induced diabetic mouse liver. 
Expression decreased when hepatocytes were treated 
with either rapamycin or LY 294002, suggesting that 
PFKFB3 regulation is phosphoinositide 3-kinase-Akt-
mammalian target of rapamycin dependent (Duran et 
al., 2009). 
Inflamatories diseases (arthritis and 
coeliac disease) 
Note 
Rheumatoid arthritis (RA) and coeliac disease (CD) are 
two autoimmune disorders which have similarities in 
their pathogenesis. In a meta-analysis of Dutch and UK 
data sets, shared association with six loci, one of them 
being PFKFB3 (Coenen et al., 2009). The 
proinflammatory cytokine interleukin (IL)-6 enhanced 
glycolysis in mouse embryonic fibroblasts and human 
cell lines through STAT3 activation which enhanced 
the expression of the glycolytic PFKFB3 isoenzyme 
(Ando et al., 2010). Furthermore, cooperation of 
adenosine with macrophage Toll-4 receptor agonists 
leads to increased glycolytic flux through the enhanced 
expression of PFKFB3 gene, showing that, in 
macrophages, endogenously generated adenosine 
cooperates with bacterial components to increase 
PFKFB3 isoenzyme activity, resulting in greater Fru-
2,6-P2 accumulation. This process enhances the 
glycolytic flux and favours ATP generation helping to 
develop and maintain the long term defensive and 
reparative functions of the macrophages (Ruiz-Garcia 
et al., 2011). 
Osteoporosis 
Note 
PFKFB3 has been also associated with osteoclast 
differentiation by the immune system response or to 
various stimuli (Xiao et al., 2012). 
Targeting PFKFB3 for cancer therapy 
Note 
PFKFB3 plays an important role in cancer cell 
metabolism and it has been considered as a potential 
target for cancer therapy. Different authors reported 
that PFKFB3 isoforms suppression inhibited 
anchorage-independent growth and induced cell-cycle 
delay, proposing that PFKFB3 protein product may 
serve as an essential downstream metabolic mediator of 
oncogenic ras (Calvo et al., 2006; Telang et al., 2006). 
The JAK2V617F oncogene requires expression of 
PFKFB3 for cell growth and increased metabolic 
activity. JAK2V617F as well as active STAT5 
increases the expression of PFKFB3, which is required 
for JAK2V617F-dependent lactate production, 
oxidative metabolic activity and glucose uptake. 
Targeted Knockdown of PFKFB3 limited cell growth 
under normoxic and hypoxic conditions and blocked in 
vivo tumor formation in mice (Reddy et al., 2012). 
Clinical development of PFKFB3 inhibitors as 
chemotherapeutic agents has been published (Clem et 
al., 2008, Seo et al., 2011).  
For example, a cell-permeable dipyridinyl-propenone 
(3PO) compound that selectively blocks PFK-2 (6-
phosphofructo-2-kinase) activity has been found 
(Telang et al., 2006). 3PO decreases Fru-2,6-P2 and 
lactate production, arresting proliferation of 
transformed cells and suppressing tumor growth in 
several xenograft mouse models (Telang et al., 2006, 
Clem et al., 2008).  
In addition, other small molecule inhibitors (N4A, 
YN1) have been identified. When tested on cultured 
cancer cells both, N4A and YN1, inhibited PFKFB3, 
decreasing Fru-2,6-P2 concentration and glycolysis and, 
ultimately, led to cell death (Seo et al., 2011). 
KO and transgenic animals 
Note 
Models of KO and transgenic animals have been 
developed showing that after disruption of the mouse 
PFKFB3 gene, no homozygous PFKFB3 (-/-) embryos 
were detected after 8 days of embryogenesis, indicating 
that the loss of PFKFB3 activity via targeted disruption 
of the gene leads to loss of embryonic cell proliferation, 
differentiation, and/or implantation.  
Serial analysis of gene expression has indicated that the 
mouse PFKFB3 mRNA becomes detectable during the 
blastocyst stage of embryogenesis.  
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In contrast, normal phenotype is observed in PFKFB3 
(+/-) mice despite the 50% reduction in PFKFB3 
expression and activity (Chesney et al., 2005).  
Using PFKFB3-disrupted (PFKFB3+/-) mice, it has 
been shown that the animals are protected against diet-
induced insulin resistance and adipose tissue 
inflammatory response (Huo et al., 2010). 
A transgenic mouse model that overexpressed pfkfb3 
and which was subjected to diet-induced obesity 
revealed production of high Fru-2,6-P2 levels and 
changes in hepatic gene expression profiles of key 
gluconeogenic and lipogenic enzymes, as well as an 
accumulation of lipids in periportal cells, and weight 
gain (Duran et al., 2008b). 
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